Candel Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CADL Nasdaq 8731 https://www.candeltx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Candel Therapeutics Inc

Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights - Mar 30th, 2023 12:00 pm
Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day - Feb 1st, 2023 1:00 pm
Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference - Jan 12th, 2023 1:00 pm
The Independent Director of Candel Therapeutics, Inc. (NASDAQ:CADL), Joseph Papa, Just Bought A Few More Shares - Dec 13th, 2022 10:11 am
Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer - Dec 6th, 2022 9:26 pm
Candel Therapeutics to Host Virtual R&D Day on December 6, 2022 - Nov 29th, 2022 1:00 pm
Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting - Nov 18th, 2022 1:00 pm
Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma - Nov 11th, 2022 5:00 pm
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights - Nov 10th, 2022 1:00 pm
Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO - Nov 7th, 2022 1:00 pm
Candel Therapeutics Upcoming Investor Conference Participation for November - Nov 1st, 2022 12:00 pm
Penn Medicine and Boston-area biopharm firm to pursue potential solid tumor CAR T-cell therapy - Oct 27th, 2022 3:16 pm
Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models - Oct 26th, 2022 12:00 pm
Candel Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for CAN-2409 in Glioma - Sep 15th, 2022 12:00 pm
Candel Therapeutics Announces Two Executive Leadership Appointments - Sep 7th, 2022 12:00 pm
Candel Therapeutics Upcoming Investor Conference Participation - Sep 6th, 2022 12:00 pm
Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights - Aug 5th, 2022 12:00 pm
Candel Therapeutics Appoints Three New Members to its Board of Directors - Aug 1st, 2022 12:00 pm
Is Candel Therapeutics, Inc. (NASDAQ:CADL) Popular Amongst Insiders? - Jul 9th, 2022 12:32 pm
Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer - May 26th, 2022 9:30 pm